Zai Lab (ZLAB) revenue breakdown
By product, ZEJULA is the largest at 41% of fiscal 2025 revenue; NUZYRA grew fastest, 1093% a year over 4 years.
Revenue by product
Fiscal years, as Zai Lab reports them in its 10-K filings; fiscal 2025 total $457M.
| Products | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|
| ZEJULA | $7M | $32M | $94M | $145M | $169M | $187M | $189M | 41% |
| VYVGART / VYVGART Hytrulo | — | — | — | — | $10M | $94M | $94M | 21% |
| NUZYRA | — | — | $3,000 | $5M | $22M | $43M | $61M | 13% |
| OPTUNE | $6M | $16M | $39M | $47M | $47M | $40M | $48M | 11% |
| QINLOCK | — | $402,000 | $12M | $15M | $19M | $29M | $36M | 8% |
| XACDURO | — | — | — | — | — | $3M | $23M | 5% |
| AUGTYRO | — | — | — | — | — | $1M | $6M | 1% |
| Other | — | — | — | — | — | — | $717,000 | 0% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for ZLAB.
Open ZLAB in InvestinglyQuestions
Where does Zai Lab make its money?
In fiscal 2025, by product: ZEJULA $189M, VYVGART / VYVGART Hytrulo $94M, NUZYRA $61M, OPTUNE $48M, QINLOCK $36M.
From Zai Lab's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.